Jeroen C Jansen

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4289336/jeroen-c-jansen-publications-by-year.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70 papers	2,407 citations	29 h-index	48 g-index
73 ext. papers	2,785 ext. citations	4.8 avg, IF	4.11 L-index

#	Paper	IF	Citations
70	A prediction model for recurrence after translabyrinthine surgery for vestibular schwannoma: toward personalized postoperative surveillance.. *European Archives of Oto-Rhino-Laryngology*, **2022**, 1	3.5	1
69	Long-Term Quality of Life of Vestibular Schwannoma Patients: A Longitudinal Analysis.. *Otolaryngology - Head and Neck Surgery*, **2022**, 1945998221088565	5.5	0
68	Response to a letter to the editor "A prediction model for recurrence after translabyrinthine surgery for vestibular schwannoma: towards personalized postoperative surveillance".. *European Archives of Oto-Rhino-Laryngology*, **2022**, 1	3.5	1
67	Multidimensional assessment of voice quality after injection augmentation of the vocal fold with autologous adipose tissue or calcium hydroxylapatite. *European Archives of Oto-Rhino-Laryngology*, **2021**, 1	3.5	0
66	Long-term voice outcomes of laryngeal framework surgery for unilateral vocal fold paralysis. *European Archives of Oto-Rhino-Laryngology*, **2021**, 1	3.5	0
65	The impact of vestibular schwannoma and its management on employment. *European Archives of Oto-Rhino-Laryngology*, **2021**, 1	3.5	0
64	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 459-471	5.6	1
63	A ‘Final Destination injury’: Penetrating trauma of the neck and a pneumomediastinum by a metal part shot from a lawnmower. *Trauma Case Reports*, **2021**, 31, 100379	0.5	0
62	Management and outcome of middle ear adenomatous neuroendocrine tumours: A systematic review. *Oral Oncology*, **2021**, 121, 105465	4.4	0
61	EGFR and VEGFR as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region. *Cancers*, **2020**, 12,	6.6	9
60	Evaluation of the modified Pittsburgh classification for predicting the disease-free survival outcome of squamous cell carcinoma of the external auditory canal. *Head and Neck*, **2020**, 42, 3609-3622	4.2	6
59	Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma. *Journal of Medical Genetics*, **2020**, 57, 96-103	5.8	8
58	Increased Mortality in but Not in Pathogenic Variant Carriers. *Cancers*, **2019**, 11,	6.6	7
57	Mathematical Models for Tumor Growth and the Reduction of Overtreatment. *Journal of Neurological Surgery, Part B: Skull Base*, **2019**, 80, 72-78	1.5	4
56	Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 438-445	5.6	38
55	Nationwide study of patients with head and neck paragangliomas carrying SDHB germline mutations. *BJS Open*, **2018**, 2, 62-69	3.9	4
54	The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers. *Clinical Genetics*, **2018**, 93, 60-66	4	33

53	Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers. *European Journal of Human Genetics*, **2018**, 26, 1339-1347	5.3	6
52	The phenotype of germline mutation carriers: a nationwide study. *European Journal of Endocrinology*, **2017**, 177, 115-125	6.5	27
51	Quality of Life in 807 Patients with Vestibular Schwannoma: Comparing Treatment Modalities. *Otolaryngology - Head and Neck Surgery*, **2017**, 157, 92-98	5.5	35
50	Age and Tumor Volume Predict Growth of Carotid and Vagal Body Paragangliomas. *Journal of Neurological Surgery, Part B: Skull Base*, **2017**, 78, 497-505	1.5	11
49	Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. *Oncotarget*, **2017**, 8, 14525-14536	3.3	13
48	Measurement of head and neck paragangliomas: is volumetric analysis worth the effort? A method comparison study. *Clinical Otolaryngology*, **2016**, 41, 571-8	1.8	3
47	Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers. *Human Molecular Genetics*, **2016**, 25, 3715-3728	5.6	11
46	No evidence for increased mortality in SDHD variant carriers compared with the general population. *European Journal of Human Genetics*, **2015**, 23, 1713-6	5.3	7
45	Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E1386-93	5.6	55
44	Emotional intelligence in association with quality of life in patients recently diagnosed with vestibular schwannoma. *Otology and Neurotology*, **2014**, 35, 1650-7	2.6	13
43	Phenotype of SDHB mutation carriers in the Netherlands. *Familial Cancer*, **2014**, 13, 651-7	3	9
42	Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. *BMC Medical Genetics*, **2014**, 15, 111	2.1	33
41	Carotid body tumors are not associated with an increased risk for sleep-disordered breathing. *Sleep and Breathing*, **2014**, 18, 103-9	3.1	6
40	Jugular and vagal paragangliomas: Systematic study of management with surgery and radiotherapy. *Head and Neck*, **2013**, 35, 1195-204	4.2	122
39	Results from craniocaudal carotid body tumor resection: should it be the standard surgical approach?. *European Journal of Vascular and Endovascular Surgery*, **2013**, 46, 624-9	2.3	21
38	Regression and local control rates after radiotherapy for jugulotympanic paragangliomas: systematic review and meta-analysis. *Radiotherapy and Oncology*, **2013**, 106, 161-8	5.3	34
37	Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients. *Oral Oncology*, **2013**, 49, 15-9	4.4	82
36	High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. *European Journal of Human Genetics*, **2013**, 21, 469-70	5.3	28

35	Quality of life is decreased in patients with paragangliomas. *European Journal of Endocrinology*, **2013**, 168, 689-97	6.5	15
34	Effects of octreotide therapy in progressive head and neck paragangliomas: case series. *Head and Neck*, **2013**, 35, E391-6	4.2	16
33	No difference in phenotype of the main Dutch SDHD founder mutations. *Clinical Endocrinology*, **2013**, 79, 824-31	3.4	6
32	Validating the Penn Acoustic Neuroma Quality Of Life Scale in a sample of Dutch patients recently diagnosed with vestibular schwannoma. *Otology and Neurotology*, **2013**, 34, 952-7	2.6	24
31	Case of spontaneous regression of carotid body tumor in a SDHD mutant: a discussion on potential mechanisms based on a review of the literature. *World Journal of Surgical Oncology*, **2012**, 10, 218	3.4	2
30	Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. *International Journal of Cancer*, **2012**, 131, E74-85	7.5	73
29	Head-and-neck paragangliomas are associated with sleep-related complaints, especially in the presence of carotid body tumors. *Sleep and Breathing*, **2012**, 16, 527-34	3.1	2
28	High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands. *Clinical Genetics*, **2012**, 81, 284-8	4	43
27	Validation of a gene expression signature for assessment of lymph node metastasis in oral squamous cell carcinoma. *Journal of Clinical Oncology*, **2012**, 30, 4104-10	2.2	59
26	Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. *Clinical Endocrinology*, **2011**, 75, 650-5	3.4	38
25	Normal life expectancy for paraganglioma patients: a 50-year-old cohort revisited. *Skull Base*, **2011**, 21, 385-8		16
24	Two immigrants with tuberculosis of the ear, nose, and throat region with skull base and cranial nerve involvement. *Case Reports in Medicine*, **2011**, 2011, 675807	0.7	7
23	SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. *Clinical Cancer Research*, **2011**, 17, 247-54	12.9	116
22	The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. *European Journal of Human Genetics*, **2010**, 18, 62-6	5.3	25
21	Pheochromocytomas detected by biochemical screening in predisposed subjects are associated with lower prevalence of clinical and biochemical manifestations and smaller tumors than pheochromocytomas detected by signs and symptoms. *European Journal of Endocrinology*, **2010**, 163, 121-7	6.5	16
20	Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 209-14	5.6	86
19	CD44 expression predicts local recurrence after radiotherapy in larynx cancer. *Clinical Cancer Research*, **2010**, 16, 5329-38	12.9	134
18	SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. *Lancet Oncology, The*, **2010**, 11, 366-72	21.7	227

17	Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. *BMC Medical Genetics*, **2010**, 11, 92	2.1	44
16	Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients. *Endocrine-Related Cancer*, **2009**, 16, 929-37	5.7	14
15	Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas. *Endocrine-Related Cancer*, **2009**, 16, 527-36	5.7	18
14	The first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients. *BMC Medical Genetics*, **2009**, 10, 34	2.1	32
13	Reduced quality of life in patients with head-and-neck paragangliomas. *European Journal of Endocrinology*, **2008**, 158, 247-53	6.5	21
12	Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1245-8	5.6	60
11	Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. *BMC Medical Genetics*, **2006** , 7, 1	2.1	86
10	Management of vagal paraganglioma: is operative resection really the best option?. *Surgery*, **2005**, 137, 225-8	3.6	37
9	Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. *European Journal of Endocrinology*, **2005**, 152, 87-94	6.5	35
8	The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features. *Journal of Medical Genetics*, **2004**, 41, e99	5.8	49
7	Recurrent Rhabdoid Meningioma: Case Report. *Skull Base*, **2003**, 13, 51-54		8
6	Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. *Genes Chromosomes and Cancer*, **2001**, 31, 274-81	5	119
5	Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. *Cancer*, **2000**, 88, 2811-2816	6.4	196
4	Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. *Cancer*, **2000**, 88, 2811-6	6.4	49
3	Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands. *American Journal of Human Genetics*, **1998**, 63, 468-73	11	29
2	First experiences with genetic counselling based on predictive DNA diagnosis in hereditary glomus tumours (paragangliomas). *Journal of Medical Genetics*, **1996**, 33, 379-83	5.8	43
1	Confinement of PGL, an imprinted gene causing hereditary paragangliomas, to a 2-cM interval on 11q22-q23 and exclusion of DRD2 and NCAM as candidate genes. *European Journal of Human Genetics*, **1996**, 4, 267-73	5.3	33